Masitinib ALS Follow-Up Reported Higher 5-Year Survival

Masitinib ALS Follow-Up Reported Higher 5-Year Survival

TL;DR: A 2026 medRxiv preprint reanalyzed long-term survivors from the AB10015 ALS trial and reported that masitinib-treated patients had higher 5-year survival than historical benchmarks, but the analysis was post hoc, sponsor-supported, and lacked long-term placebo follow-up. Key Findings Five-year survival was 42.3%: 55 of 130 patients assigned to masitinib 4.5 mg/kg/day were alive at …

Read more

Neural Extracellular Matrix Remodeling Shapes Neurological Disease and Brain Plasticity

Neural Extracellular Matrix Remodeling Shapes Neurological Disease and Brain Plasticity

TL;DR: A 2026 review in Nature Reviews Neurology argued that neural extracellular matrix (ECM), the protein-and-glycan scaffold around central nervous system cells, is an active regulator of brain plasticity and neurological disease. Key Findings Multiple ECM forms: The review describes perineuronal nets, perisynaptic ECM, periaxonal coats, and diffuse interstitial ECM. Brain function link: Neural ECM …

Read more

MSA Drug Repurposing Review Highlighted Ubiquinol and Exenatide Signals

MSA Drug Repurposing Review Highlighted Ubiquinol and Exenatide Signals

TL;DR: A 2026 review in Translational Neurodegeneration found that most repurposed multiple system atrophy drugs failed to show disease-slowing effects in trials, while ubiquinol produced the clearest placebo-controlled motor-progression signal. Key Findings No proven disease-modifying therapy: Multiple system atrophy remains a rapidly progressive neurodegenerative disease without an approved treatment that slows progression. Four target classes …

Read more

Brain Iron Deficiency Sensitized a Dopamine-Opioid Restless Legs Pathway

Brain Iron Deficiency Sensitized a Dopamine-Opioid Restless Legs Pathway

TL;DR: A 2026 mouse study in Neuropsychopharmacology found that brain iron deficiency made an opioid-responsive striatal pathway unusually sensitive to D1 dopamine receptor stimulation, pointing to a possible circuit mechanism for restless legs syndrome and opioid-withdrawal restlessness. Key Findings Iron-deficient mouse model: Researchers used a low-iron diet to create brain iron deficiency (BID), a rodent …

Read more

Monthly Lecanemab Maintained Alzheimer’s Blood Biomarker Changes After 18 Months

Monthly Lecanemab Maintained Alzheimer's Blood Biomarker Changes After 18 Months

TL;DR: A 2026 study in Alzheimer’s & Dementia: Translational Research & Clinical Interventions used lecanemab pharmacokinetic/pharmacodynamic modeling in early Alzheimer’s disease and found that blood biomarkers worsened after treatment stopped, while monthly maintenance dosing after 18 months was predicted to preserve most p-tau181 and GFAP, an astrocyte-inflammation protein. Key Findings Three plasma biomarkers improved: Lecanemab …

Read more

Il6 Deficiency Worsened Parkinson’s Mouse Damage by Sex

Il6 Deficiency Worsened Parkinson's Mouse Damage by Sex

TL;DR: A 2026 study in Genes & Diseases found that Il6 deficiency, meaning loss of the gene for interleukin-6, worsened Parkinson’s-like motor and dopamine-system injury in mice. Key Findings Il6 knockout worsened movement: Mice lacking Il6 performed worse after MPTP, a toxin commonly used to model Parkinson’s-like dopamine injury. Female knockout mice showed earlier damage: …

Read more

NYUCI-ES Adapted Dementia Caregiver Counseling for Chinese and Korean American Families

NYUCI-ES Adapted Dementia Caregiver Counseling for Chinese and Korean American Families

TL;DR: A 2026 descriptive study in JMIR Formative Research reported that the NYUCI-ES dementia-caregiver program required 24 documented cultural adaptations before and during delivery to Chinese and Korean American caregivers. Key Findings 24 adaptation strategies: Researchers identified 24 major changes to the dementia-caregiver intervention. Five adaptation elements: Changes were grouped into content, context, relationship fidelity, …

Read more

Amyloid PET Became Central to Alzheimer’s Antibody Eligibility

Amyloid PET Became Central to Alzheimer’s Antibody Eligibility

TL;DR: A 2026 narrative review in the Japanese Journal of Radiology reported that Alzheimer’s brain positron emission tomography (PET) imaging has shifted from supportive diagnosis toward treatment selection because amyloid PET is now central to confirming eligibility for anti-amyloid antibody therapy. Key Findings Three PET roles: The review separated FDG-PET, amyloid PET, and tau PET …

Read more

AI-Assisted Bayesian Inference Found Gamma-Secretase Alzheimer Pathways

AI-Assisted Bayesian Inference Found Gamma-Secretase Alzheimer Pathways

TL;DR: A 2026 medRxiv preprint applied ChatGPT-4o-assisted Bayesian-frequentist hybrid inference to Alzheimer’s single-nucleus RNA-seq data and identified gamma-secretase and HP1 transcription pathways that a no-evidence frequentist setting did not recover. Key Findings 427 ROSMAP samples: The application used postmortem prefrontal cortex single-nucleus RNA-seq data from 427 Religious Orders Study and Memory and Aging Project samples. …

Read more

Under-Mattress Sleep Sensors Predicted Next-Day Dementia Agitation Risk

Under-Mattress Sleep Sensors Predicted Next-Day Dementia Agitation Risk

TL;DR: A 2026 preprint in medRxiv found that under-mattress sleep sensors associated lower nighttime respiratory rate and more unstable nighttime movement with higher odds of next-day agitation in dementia, while the same features did not predict how severe agitation became once it occurred. Key Findings 55 dementia patients supplied the main dataset: Researchers matched 333 …

Read more